[A20-24] Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2020
Project no.:
A20-24
Commission:
Commission awarded on 11.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-67 | Romosozumab (osteoporosis) - Addendum to Commission A20-24 | Commission completed |
Federal Joint Committee (G-BA)
2020-09-03 A G-BA decision was published.